Recombinant Protein Market, by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), by Application (Drug Discovery & Development, Biopharmaceutical Production,

Recombinant Protein Market, by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), by Application (Drug Discovery & Development, Biopharmaceutical Production, Basic Research, and Others), by End User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Recombinant proteins are used in development of novel therapies for severe chronic diseases such as cancer and other rare diseases. Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology. Depending on the type of the protein, recombinant proteins are classified into hormones, growth factor, cytokines, plasma protein factor, recombinant metabolic enzymes, and others. Manufacturers such as Biocon, Ltd., Eli, Lilly, and Company, Genentech, Inc., Novo Nordisk Pharmatech A/S, Prospec-Tany Technogene Ltd., Abcam plc, and BPS Bioscience, Inc. offer recombinant proteins for various applications such as drug discovery and development. Advancements in rDNA technology such as Clustered regularly interspaced short palindromic repeats (CRISPR) technique has complemented recombinant protein production. Furthermore, advancements in associated processes such as protein purification methods, alternative expression technologies, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized the recombinant protein production processes.

Market Dynamics

Increasing demand for recombinant proteins for basic research has supported growth of recombinant protein market. Manufacturers are involved in recombinant protein product innovation in order to improve research outcomes along with improvements in other areas such as expression techniques, and protein purification techniques, which compliments growth of the recombinant protein market. The market is expected to gain significant growth, owing increasing adoption of biologics and biosimilars, which in turn, impact recombinant proteins market growth, along with rising prevalence of chronic diseases such as cancer. Furthermore, availability of wide number of innovative recombinant proteins from various sources such as human and animal, lack of suitable alternative for basic protein related therapies research, and increasing demand for biological products is expected to drive growth of the global recombinant protein market.

Key features of the study:

• This report provides an in-depth analysis of the global recombinant protein market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global recombinant protein market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global recombinant protein market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant protein market

Detailed Segmentation:

• Global Recombinant Protein Market, By Product Type:
• Hormones
• Growth Factor
• Cytokines
• Plasma Protein Factor
• Recombinant Metabolic Enzymes
• Immune Checkpoint Regulators
• Others
• Global Recombinant Protein Market, By Application:
• Drug Discovery & Development
• Biopharmaceutical Production
• Basic Research
• Others
• Global Recombinant Protein Market, By End User:
• Biopharmaceutical Companies
• Academic & Research Institutes
• Contract Research Organizations
• Others
• Global Recombinant Protein Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Crown Bioscience, Inc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• ProSpec Tany TechnoGene, Ltd.
• BPS Bioscience, Inc.
• Sigma Aldrich Company Ltd.
• Novoprotein Scientific
• PeproTech, Inc.
• Feldan Bio, Inc.
• BioVision, Inc.
• HumanZyme, Inc.
• GenScript Biotech Corporation

“*” marked represents similar segmentation in other categories in the respective section